Compare BridgeBio Pharma Inc (BBIO) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs The Coca-Cola Co K — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while The Coca-Cola Co K trades at $86.53 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 22.5× BridgeBio Pharma Inc's market cap, and The Coca-Cola Co K pays a 2.44% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | KO | |
|---|---|---|
Market Cap | $16.61B | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $89.08 |
52-Week Low | $47.29 | $65.67 |
Enterprise Value | $18.16B | $400.93B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Coca-Cola (KO) trades at $86.48, down 0.65% on the day. The stock shows strong fundamentals with a 27.33% net income margin in 2025 and consistent earnings beats in recent quarters. Technical indicators are bullish, with the price above key support levels. Recent news highlights institutional buying and stable demand trends, while the company maintains a 64-year dividend growth streak.
Outlook is positive with a consensus price target of $95.83, implying 11% upside. Risks include regional demand volatility and high debt levels. The stock offers a reliable dividend but faces margin pressure from inflation and competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
